Biotech Values

[oc631]

i wonder if ENTA can use this data to argue that the non-nuke has a minimal contribution to efficacy in pts with 1b (and aim for a higher royalty share)

Since the ABBV drugs in the U.S. aren't co-formulated it's going to be a challenge for ENTA to track the higher royalty rates in GT1B patients using the 2-DAA combination.